Skip to content


  • Meeting abstract
  • Open Access

Phase 2/3 study of intravenous thrombolysis and hypothermia for acute treatment of ischemic stroke (ICTuS 2/3)

  • 1,
  • 1,
  • 1,
  • 2,
  • 3,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9,
  • 10,
  • 11,
  • 12,
  • 1,
  • 5,
  • 5 and
  • 13
Critical Care201216 (Suppl 2) :A13

  • Published:


  • Ischemic Stroke
  • Acute Ischemic Stroke
  • Interim Analysis
  • Barthel Index
  • Ischemic Stroke Patient


The ICTuS trial showed feasibility of endovascular hypothermia for acute ischemic stroke [1]; ICTuS L confirmed safety and feasibility of endovascular hypothermia during thrombolysis [2]. The ICTuS 2/3 study seeks to determine whether the combination of thrombolysis and hypothermia is superior to thrombolysis alone for the treatment of acute ischemic stroke. A phase 2 study will include 450 patients to assess the safety of various protocol changes, to demonstrate sufficient recruitment, and to allow an interim analysis for futility. If pre-specified milestones are achieved the study will be enlarged to a 1,800-patient phase 3 efficacy study.


This is a prospective, randomized, single-blind, multicenter phase 2/3 study. We aim to include ischemic stroke patients treated within 3 hours of symptom onset with IV tPA (according to FDA or EMEA protocol), NIHSS ≥7 and ≤20, age 22 to 80. Patients are randomly assigned to either hypothermia permissively targeted to 33°C or normothermia. Favorable outcome is defined as a 90-day Modified Rankin score (mRS) of 0 or 1. Secondary outcome measures are: 90-day NIHSS, Barthel Index (BI), mortality, shift analysis of the mRS, global odds ratio of mRS, BI, NIHSS, incidence of symptomatic intracranial hemorrhage and 90-day Montreal Cognitive Assessment. An interim analysis for futility is planned near the end of phase 2. In addition to futility, analyses will assess the frequency of target temperature reached within 6 hours from symptom, pneumonia rate, safety profile of iced saline infusion and study-wide average enrollment rate.


The study team initiated 11 study sites in the USA and two in Europe. Enrolment began in December 2010. Currently, 37 subjects are enrolled. A full DSMB review of experience to date allowed the study to continue enrollment. A safety review after the first 50 patients is expected in late 2012.


ICTuS 2/3 is the largest trial of endovascular hypothermia for acute stroke currently running. There appear to be no safety or feasibility concerns.



NINDS grants P50NS5044148 (UCSD) and P50NS044227 (Houston).

Authors’ Affiliations

UCSD Medical Center, San Diego, CA, USA
Sarasota Memorial Hospital, Sarasota, FL, USA
University Hospital Innsbruck, Austria
Scripps Mercy Hospital, San Diego, CA, USA
University of Texas, Houston, TX, USA
St Louis University, St Louis, MO, USA
University of Erlangen, Germany
Hoag Hospital, Newport Beach, CA, USA
North Memorial Hospital, Robbinsdale, MN, USA
University of Lausanne, Switzerland
University of Alabama, Birmingham, AL, USA
St Joseph Hospital, Tampa, FL, USA
Cedars Sinai Medical Center, Los Angeles, CA, USA


  1. Lyden PD, Allgren RL, Ng K, Akins P, Meyer B, Al-Sanani F, Lutsep H, Dobak J, Matsubara BS, Zivin J: Intravascular Cooling in the Treatment of Stroke (ICTuS): early clinical experience. J Stroke Cerebrovasc Dis 2005, 14: 107-114. 10.1016/j.jstrokecerebrovasdis.2005.01.001View ArticlePubMedGoogle Scholar
  2. Hemmen TM, Raman R, Guluma KZ, Meyer BC, Gomes JA, Cruz-Flores S, Wijman CA, Rapp KS, Grotta JC, Lyden PD: Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. Stroke 2010, 41: 2265-2270. 10.1161/STROKEAHA.110.592295PubMed CentralView ArticlePubMedGoogle Scholar


© Hemmen et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.